SCHEMBL11018441

SCHEMBL11018441

Cc1nc(=O)[nH]c(=O)[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13984967 0.72
SCHEMBL18037706 0.69
SCHEMBL1096504 0.69
SCHEMBL8312414 0.67
SCHEMBL11842484 0.67 LMNA (0.45)
SCHEMBL15870001 0.67 ADORA1 (0.41)
SCHEMBL21324849 0.67 L3MBTL1 (0.57)
SCHEMBL1612973 0.67
SCHEMBL31495235 0.67
SCHEMBL17671749 0.67 MAPT (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120004863-A ALK protein degradation agent and application thereof in resisting tumor 江苏天士力帝益药业有限公司 2025-05-16 CN disclosed
CN-119528836-A Method for synthesizing methylated azauracil derivative 桂林理工大学 2025-02-28 CN disclosed
WO-2023193818-A1 METHOD FOR SYNTHESIZING POLYSUBSTITUTED TRIAZINE COMPOUND 湖北九康通生物医药有限公司 2023-10-12 WO disclosed
US-10028961-B2 Therapeutically active compounds and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2018-07-24 US disclosed
US-10017495-B2 Therapeutically active compounds and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2018-07-10 US disclosed
US-9751863-B2 Therapeutically active compounds and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2017-09-05 US disclosed
US-20170107194-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2017-04-20 US disclosed
US-9579324-B2 Therapeutically active compounds and their methods of use AGIOS PHARMACEUTICALS, INC (US) 2017-02-28 US disclosed
US-20170037031-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2017-02-09 US disclosed
US-20160237071-A1 T-TYPE CALCIUM CHANNEL INHIBITOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-08-18 US disclosed
US-20160220572-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-08-04 US disclosed
US-20160220572-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-08-04 US disclosed
US-20160159771-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-06-09 US disclosed
EP-0154906-A2 3-Cyclopropylmethyl-1,3,5-triazine-2,4-dione BAYER AG (DE) 1985-09-18 EP disclosed
US-4209619-A HEXAZINONE AND UREA E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-06-24 US disclosed
US-4174445-A INSECTICIDES BAYER AKTIENGESELLSCHAFT (DE) 1979-11-13 US disclosed
US-4048315-A NEMATOCIDES BAYER AKTIENGESELLSCHAFT (DT) 1977-09-13 US disclosed